Resources for Researchers
Non-government Links
NIAID Antiviral Testing ProgramWeb site: http://niaid-aacf.org/
The NIAID Antiviral Testing Program supports screening systems and animal models for the assessment of the efficacy and toxicity of potential therapeutic approaches for important human viral infections. The main objective of this program is to facilitate the identification of antiviral agents with the potential for treatment of viral infections of public health importance, including those for newly emerging infections, and those that are not a high priority for the pharmaceutical industry. NIAID ensures that the compound supplier's intellectual property rights are protected. The viruses and models covered under this program are:
In Vitro Screens
- Herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-8)
- Respiratory viruses (Flu A and B, RSV, PIV, Measles, Rhino, Adeno, SARS)
- Hepatitis B virus, Hepatitis C virus
- Papillomaviruses, BK virus
- Biodefense: Orthopoxviruses (Vaccinia, Cowpox), VEE, Punta Toro, Pichinde, Yellow fever, West Nile, dengue
Animal Models
- HCV/-SCID/bg/uPA chimeric
- Herpesviruses (HSV-1, HSV-2, MCMV, GPCMV, HCMVSCID-hu)
- Respiratory viruses (Flu A & B, RSV, PIV-3, MV)
- Hepatitis viruses (WHV, HBVtransgenic)
- Papillomaviruses (Shope, HPVSCID-hu)
- Hamster scrapie in hampster-prion transgenic mice
- Biodefense: Orthopoxviruses (Vaccinia, Cowpox, Ectromelia), Punta Toro, Pichinde, Banzi, Semliki Forest, West Nile
Collaborative Antiviral Study Group (CASG)Web site: http://www.casg.uab.edu/
The CASG is a multi-institutional collaborative network funded by NIAID to conduct clinical trials and evaluate experimental therapies for viral infections. It comprises investigators at approximately 50 clinical research institutions and a Central Unit that serves as the core administrative, research, laboratory, biostatistical, and data management component of the CASG. The CASG infrastructure makes it possible to respond expeditiously to promising new therapies as well as unanticipated emergent clinical priorities.
back to top |